Navigation Links
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
Date:2/23/2011

HORSHAM, Pa., Feb. 23, 2011 /PRNewswire/ -- Centocor Ortho Biotech Inc. (Centocor) today received a decision from the Court of Appeals for the Federal Circuit in Washington, D.C. overturning a 2009 federal court jury verdict that awarded the company $1.8 billion after finding Abbott Laboratories liable for patent infringement.

A panel of the court ruled that the patent relating to Centocor anti-tumor necrosis factor (TNF) -alpha rheumatoid arthritis treatments was invalid.

"We are disappointed by the decision," said Rob Bazemore, president of Centocor Ortho Biotech Inc.  "We are considering whether to ask for reconsideration by the panel or by the court of appeals as a whole."

The original verdict was returned in June 2009 by a U.S. District Court jury in Marshall, Texas.  The patent is co-owned by New York University and Centocor, the exclusive licensee.

About Centocor Ortho Biotech Inc.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology, and oncology. Built upon a pioneering history, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care. For more information about Centocor Ortho Biotech, visit www.CentocorOrthoBiotech.com.  Centocor Ortho Biotech Inc. is a wholly owned subsidiary of Johnson & Johnson (NYSE: JNJ).

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Centocor Ortho Biotech Inc. and/or Johnson & Johnson. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.


'/>"/>
SOURCE Centocor Ortho Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
3. Pharma CI Conference Amy Yueh Pays $52,000 to Apaporis LLC to Satisfy Judgment Against Her In Superior Court Of New Jersey Case
4. Montana Supreme Court Decision Endangers Most Vulnerable Citizens
5. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
6. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
7. CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures
8. Texas Court Asked to Appoint Receiver for Key Subsidiary of TSX Listed Northstar Healthcare, Inc. (TSX NHC) on Claims of Mismanagement and Breach of Fiduciary Duty
9. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
10. Appellate Court Decides in Favor of Fenwal
11. CRESTOR® Patent Upheld By US Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... provides evidence that an old drug may provide relief for ... that will be presented at the American Academy of ... , April 22 to 28, 2017. When ... drug levodopa has long been considered the gold standard, improving ... the effects of the medication can partially wear off more ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... and BLOOMINGTON, Minn. ... (NASDAQ: IMMY ) ("Imprimis"), an ophthalmology-focused ... Lens ("Precision Lens"), today announced the signing of ... agreement, Precision Lens will deploy a dedicated sales ... geographies in the U.S., primarily focused in 13 ...
Breaking Medicine Technology:
(Date:4/24/2017)... , ... April 24, 2017 , ... Ridgecrest Herbals makes ... sustainability, innovate new strategies to reduce waste, and support renewable energy. They believe this ... look to nature to find solutions for health issues, and maintain that destroying the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Today, Bright Pink , a national non-profit organization focusing ... a new CEO. , Bright Pink is proud to announce Katie Thiede as their ... to a new role as Chairman of the Board and launched a national search ...
(Date:4/24/2017)... ... 2017 , ... The John P. McGovern Museum of Health and Medical Science ... their cognitive health, and share results with their physicians. Members and guests can sign ... website. , BrainCheck founder, Dr. David Eagleman, formerly at Baylor College of Medicine and ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... advisor within the telehealth industry, announces the company’s VideoMedicine mobile platform has launched ... providers. Available 24 hours a day, Quick Care provides patients with the option ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health ... anxiety levels in people with addiction who are served by MAP’s patient engagement ... wearable device that monitors heart and breath rates to identify anxiety levels and ...
Breaking Medicine News(10 mins):